Ignite Creation Date:
2024-05-05 @ 9:09 PM
Last Modification Date:
2024-10-26 @ 10:00 AM
Study NCT ID:
NCT00829465
Status:
COMPLETED
Last Update Posted:
2016-04-01
First Post:
2008-12-22
Brief Title:
Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma
Sponsor:
Eastern Hepatobiliary Surgery Hospital
Organization:
Eastern Hepatobiliary Surgery Hospital
Study Overview
Official Title:
Clinical Research of in the Treatment of Unresectable Hepatocellular Carcinoma
Status:
COMPLETED
Status Verified Date:
2016-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Liver cancer is a highly invasive malignancy and the rate of surgical resection is no more than 28 After diagnosis the average survival rate of patient is less than 50 in 6 month less than 24 in 1 year and 5 in 5 year The TACE treatment under the theoretical basis of blood supply of Liver cancer is obviously better than the other non-surgical therapy in terms of tumor regression AFP decrease survival time and the evaluation of the quality of life However its overall effect is not yet satisfactory As a result concerning the research of drug for liver cancer and improving the overall efficacy of the treatment of liver cancer has a very real and important clinical significance and social value Licartin Iodine-131-Labeled Metuximab injection is a antibody drug with new target and the only drug that China own the intellectual property rights It has specific high affinity with HAb18GCD147 the liver cell membrane antigen Labeled 131I is taken to the liver tissue owning high-dose concentration and releasing β particles to liver cancer cells to and kill cancer cells
The Second Military Medical University Eastern Hepatobiliary Surgery Hospital planed to use the treatment of Licartin combined with TACE for the patients of unresectable hepatocellular carcinoma and evaluate the difference of tumor size AFP change TTP the overall survival rate between different treatment group
The Second Military Medical University Eastern Hepatobiliary Surgery Hospital planed to use the treatment of Licartin combined with TACE for the patients of unresectable hepatocellular carcinoma and evaluate the difference of tumor size AFP change TTP the overall survival rate between different treatment group
Detailed Description:
Liver cancer is a highly invasive malignancy and the rate of surgical resection is no more than 28 The TACE treatment under the theoretical basis of blood supply of Liver cancer is obviously better than the other non-surgical therapy in terms of tumor regression AFP decrease survival time and the evaluation of the quality of life Licartin injection is a antibody drug with new target and the only drug that China own the intellectual property rights It has specific high affinity with HAb18GCD147 the liver cell membrane antigen Labeled 131I is taken to the liver tissue owning high-dose concentration and releasing β particles to liver cancer cells to and kill cancer cells
The Second Military Medical University Eastern Hepatobiliary Surgery Hospital planed to use the treatment of Licartin combined with TACE for the patients of unresectable hepatocellular carcinoma and evaluate the difference of tumor size AFP change TTP the overall survival rate between different treatment group
The Second Military Medical University Eastern Hepatobiliary Surgery Hospital planed to use the treatment of Licartin combined with TACE for the patients of unresectable hepatocellular carcinoma and evaluate the difference of tumor size AFP change TTP the overall survival rate between different treatment group
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None